Today: 9 April 2026
Subscribe
Browse Category

NASDAQ:IBRX 16 January 2026 - 25 March 2026

ImmunityBio (IBRX) Stock Tumbles After FDA Warning on Anktiva Claims

ImmunityBio (IBRX) Stock Tumbles After FDA Warning on Anktiva Claims

ImmunityBio shares fell 21.1% Tuesday after the FDA posted a warning letter accusing the company of false or misleading claims about its cancer drug Anktiva in a TV ad and podcast. The FDA said the materials suggested Anktiva could cure or prevent all cancer, which is not approved. ImmunityBio has 15 working days to respond. Anktiva accounted for nearly all of the company’s $113 million in 2025 revenue.
25 March 2026
··
ImmunityBio stock jumps again in premarket as ANKTIVA sales surge puts IBRX in focus

ImmunityBio stock jumps again in premarket as ANKTIVA sales surge puts IBRX in focus

ImmunityBio shares rose 3.5% to $11.95 premarket Wednesday after reporting 2025 net product revenue of $113 million for Anktiva, up about 700% year over year. The company posted a 2025 net loss of $351.4 million and ended the year with $242.8 million in cash. Investors await a March FDA meeting on recombinant BCG. Director Barry J. Simon sold 175,000 shares last week under a prearranged plan.
25 February 2026
·
ImmunityBio (IBRX) stock rises premarket after ANKTIVA sales surge, cash burn still in view

ImmunityBio (IBRX) stock rises premarket after ANKTIVA sales surge, cash burn still in view

ImmunityBio shares rose about 1% to $8.70 premarket after reporting ANKTIVA net product revenue of $113 million for 2025, up roughly 700% from 2024. The company posted a $351.4 million net loss and ended the year with $242.8 million in cash. ANKTIVA is now authorized in 33 countries, including recent European approval. Traders are watching cash burn and upcoming regulatory milestones.
23 February 2026
·
ImmunityBio stock jumps into the weekend as IBRX traders eye an FDA resubmission clock

ImmunityBio stock jumps into the weekend as IBRX traders eye an FDA resubmission clock

ImmunityBio shares (IBRX) closed Friday up 6% at $6.25, bucking broader market declines. The company faces dilution risk after amending a $505 million convertible note with Nant Capital. Attention is on FDA feedback for ANKTIVA’s label expansion in papillary bladder cancer, with a regulatory submission expected within 30 days. The next major event is the late-February ASCO GU conference.
1 February 2026
··
ImmunityBio stock rebounds: FDA scrutiny, a $505 million note and the next catalyst for IBRX

ImmunityBio stock rebounds: FDA scrutiny, a $505 million note and the next catalyst for IBRX

ImmunityBio shares climbed 5.9% to $6.26 Friday, rebounding from early losses despite declines in major biotech ETFs. The move followed a STAT News report that Chairman Patrick Soon-Shiong misrepresented an FDA meeting on Anktiva’s label expansion. Investors also tracked dilution risk after ImmunityBio amended a $505 million convertible note to allow partial conversions into stock.
30 January 2026
·
ImmunityBio (IBRX) stock slips after SEC filing tweaks $505 million insider note — what traders watch next

ImmunityBio (IBRX) stock slips after SEC filing tweaks $505 million insider note — what traders watch next

ImmunityBio shares fell 1.6% to $6.35 after a filing showed looser conversion terms on a $505 million note held by an affiliate of executive chairman Patrick Soon-Shiong. The amendment allows partial conversions into stock, raising dilution concerns. About 16.8 million shares traded as the stock ranged from $6.28 to $6.92. New glioblastoma data will be presented Jan. 31.
26 January 2026
·
ImmunityBio stock tumbles after glioblastoma update; what to watch before Monday

ImmunityBio stock tumbles after glioblastoma update; what to watch before Monday

ImmunityBio shares fell 12.1% to $6.45 Friday after the company previewed new data from its Phase 2 glioblastoma trial, with full results due Jan. 31. The stock traded heavily between $7.88 and $6.43. Median overall survival in the study was “not yet reached” as of Jan. 22, with 19 of 23 patients alive. Investors are watching for more details on durability, safety, and trial design.
25 January 2026
·····
ImmunityBio (IBRX) stock slides after glioblastoma update — here’s what investors watch next week

ImmunityBio (IBRX) stock slides after glioblastoma update — here’s what investors watch next week

ImmunityBio shares fell 12.1% to $6.45 Friday after reporting median overall survival has not been reached in its Phase 2 glioblastoma trial. BTIG raised its price target to $9 and kept a Buy rating. The company said the FDA requested more data for its ANKTIVA bladder cancer application but no new trials. Preliminary 2025 net product revenue was reported at $113 million, up about 700% year-over-year.
24 January 2026
·
ImmunityBio stock price swings as new glioblastoma data hits; IBRX traders eye Jan. 31 update

ImmunityBio stock price swings as new glioblastoma data hits; IBRX traders eye Jan. 31 update

ImmunityBio shares rose 2.7% to $7.54 Friday after updated Phase 2 data showed 19 of 23 glioblastoma patients still alive, with median overall survival unreached. Over 31 million shares traded as investors awaited more trial details at a Jan. 31 summit. The company reported 2025 ANKTIVA revenue of $113 million and year-end cash of $242.8 million. The stock has tripled in three weeks.
23 January 2026
·
ImmunityBio (IBRX) stock slips premarket after FDA maps fresh ANKTIVA resubmission route in bladder cancer

ImmunityBio (IBRX) stock slips premarket after FDA maps fresh ANKTIVA resubmission route in bladder cancer

ImmunityBio shares fell 5.9% to $6.10 premarket after announcing an FDA meeting on possible resubmission of its ANKTIVA bladder-cancer drug. The FDA previously rejected the application for BCG-unresponsive papillary disease and has now requested more data. ImmunityBio plans to submit the information within 30 days. The company cites long-term trial data showing a 58.2% 12-month disease-free survival rate.
21 January 2026
·
Why ImmunityBio stock jumped nearly 40%: ANKTIVA sales surge and a fresh trial timeline

Why ImmunityBio stock jumped nearly 40%: ANKTIVA sales surge and a fresh trial timeline

ImmunityBio shares soared 40% to $5.52 Friday after the company reported preliminary 2025 net product revenue of $113 million and new approvals for ANKTIVA in Saudi Arabia. Trading volume topped 182 million shares. Enrollment in its key bladder cancer trial is over 85% complete, with FDA submission targeted by late 2026. Early data from its CAR-NK cell therapy showed complete remission in two Waldenström lymphoma patients.
18 January 2026
··
ImmunityBio stock (IBRX) ends week up 40% on ANKTIVA sales surge, fresh trial data — what’s next

ImmunityBio stock (IBRX) ends week up 40% on ANKTIVA sales surge, fresh trial data — what’s next

ImmunityBio shares surged 39.8% to $5.52 Friday after the company projected 2025 ANKTIVA net product revenue of $113 million, up about 700% from last year. The stock rose further to $6.04 in after-hours trading. Trial enrollment for its bladder cancer study reached over 85%, and new CAR-NK data showed a 15-month complete response in Waldenström lymphoma.
18 January 2026
·
ImmunityBio stock price surges on ANKTIVA sales pop — what IBRX investors watch next

ImmunityBio stock price surges on ANKTIVA sales pop — what IBRX investors watch next

ImmunityBio shares jumped 39.9% to $5.52 Friday after reporting a sharp rise in preliminary 2025 ANKTIVA sales and positive trial updates. The company projected about $113 million in 2025 net product revenue for ANKTIVA, up nearly 700% from 2024. An interim analysis showed higher complete response rates for ANKTIVA plus BCG in bladder cancer. U.S. markets reopen Tuesday after the MLK Jr. holiday.
17 January 2026
·
ImmunityBio stock jumps 35% as ANKTIVA bladder cancer trial update puts FDA filing in view

ImmunityBio stock jumps 35% as ANKTIVA bladder cancer trial update puts FDA filing in view

ImmunityBio shares surged 35% Friday after reporting faster enrollment and positive interim results in its ANKTIVA bladder cancer trial. The company also disclosed $113 million in 2025 preliminary revenue and Saudi approval for ANKTIVA in lung cancer. Shares traded at $5.34 by midday with 133 million shares changing hands. Early data from its CD19 CAR-NK cell therapy showed complete responses in Waldenström lymphoma.
16 January 2026
···
1 2

Stock Market Today

  • Morgan Stanley's Ridham Desai Predicts Sensex at 95,000 by Dec 2026 Amid Bull Market Signal
    April 9, 2026, 6:01 AM EDT. Morgan Stanley strategist Ridham Desai forecasts the Sensex could reach 95,000 by December 2026, marking a 22% gain from the current level of 77,563. This target reflects a valuation at 23.5 times trailing earnings, slightly above the historical average of 22 times. The firm highlights India's nearly worst 12-month relative stock performance in history but notes a potential market recovery driven by stable macroeconomic factors, earnings growth, and steady policy environment. Key growth drivers include fiscal discipline, private investment, and robust domestic demand. The bull scenario sees the index soaring to 107,000 on stronger growth and lower oil prices, while risks such as high crude prices and a potential US recession could drag it down to 76,000. Overall, Indian equities appear undervalued and positioned for a rebound according to Morgan Stanley.

Latest article

Australia Stock Market Today: ASX 200 Ends at Five-Week High as Banks Offset Tech Rout

Australia Stock Market Today: ASX 200 Ends at Five-Week High as Banks Offset Tech Rout

9 April 2026
SYDNEY, April 9, 2026, 19:31 AEST Australian shares edged up on Thursday, with the S&P/ASX 200 closing at a five-week high as banks carried the benchmark while a sharp selloff in technology shares capped the advance. The index rose 0.2% to 8,973.20, its highest finish since March 3. (Business Recorder) The move kept the market within sight of 9,000 after Wednesday’s 2.6% jump, its biggest one-day gain in a year, when a surprise U.S.-Iran ceasefire briefly pushed oil below $100 a barrel and drew buyers back into beaten-down stocks. Australian equities had fallen about 8% in March, so the rebound
UK Stock Market Today: FTSE 100 Holds Near 10,600 as Oil Rebound Tests Ceasefire Rally

UK Stock Market Today: FTSE 100 Holds Near 10,600 as Oil Rebound Tests Ceasefire Rally

9 April 2026
FTSE 100 held near 10,600 Thursday after a 2.5% rally to a one-month high, outperforming European peers as Germany’s DAX and France’s CAC 40 fell. Brent crude rebounded toward $98 on renewed U.S.-Iran ceasefire doubts. A Bank of England survey showed lenders expect mortgage demand to rise in Q2. British builders faced record cost inflation in March.
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 09.04.2026

9 April 2026
LIVEMarkets rolling coverageStarted: April 9, 2026, 12:00 AM EDTUpdated: April 9, 2026, 6:11 AM EDT Morgan Stanley's Ridham Desai Predicts Sensex at 95,000 by Dec 2026 Amid Bull Market Signal April 9, 2026, 6:01 AM EDT. Morgan Stanley strategist Ridham Desai forecasts the Sensex could reach **95,000 by December 2026**, marking a 22% gain from the current level of 77,563. This target reflects a valuation at 23.5 times trailing earnings, slightly above the historical average of 22 times. The firm highlights India's nearly worst 12-month relative stock performance in history but notes a potential market recovery driven by stable macroeconomic
Why IREN Stock Is Back in Focus as AI Ambitions Meet Funding Fears

Why IREN Stock Is Back in Focus as AI Ambitions Meet Funding Fears

8 April 2026
IREN shares rose 1.8% to $35.74 Wednesday as investors assessed its $6 billion share program and shift from bitcoin mining to AI cloud services. The company’s revenue fell to $184.7 million last quarter, with a net loss of $155.4 million. IREN recently announced a five-year, $9.7 billion AI cloud deal with Microsoft. Options trading volume hit 103,000 contracts Tuesday, with sentiment described as mixed.
Amazon Stock Could Jump 50% as Wall Street Reconsiders Its $200 Billion AI Bet

Amazon Stock Could Jump 50% as Wall Street Reconsiders Its $200 Billion AI Bet

8 April 2026
Amazon closed at $213.77 Tuesday, with BNP Paribas maintaining a $320 price target, citing strong AI demand despite Amazon’s planned $200 billion capex for 2026. The company’s February forecast of higher spending sent shares down 11.5% after hours, even as AWS revenue rose 24% to $35.6 billion in the December quarter. Alphabet and Microsoft are also ramping up AI infrastructure spending.
Go toTop